|
1
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J; International Adjuvant
Lung Cancer Trial Collaborative Group, : Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
NSCLC Meta-analyses Collaborative Group, ;
Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le
Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, et al: Adjuvant
chemotherapy, with or without postoperative radiotherapy, in
operable non-small-cell lung cancer: Two meta-analyses of
individual patient data. Lancet. 375:1267–1277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Strauss GM, Herndon JE II, Maddaus MA,
Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM,
Sugarbaker DJ, Schilsky RL, et al: Adjuvant paclitaxel plus
carboplatin compared with observation in stage IB non-small-cell
lung cancer: CALGB 9633 with the cancer and leukemia group B,
radiation therapy oncology group, and north central cancer
treatment group study groups. J Clin Oncol. 26:5043–5051. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Winton T, Livingston R, Johnson D, Rigas
J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E,
et al: Vinorelbine plus cisplatin vs. observation in resected
non-small-cell lung cancer. N Engl J Med. 352:2589–2597. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Douillard JY, Rosell R, De Lena M,
Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR,
Le Groumellec A, Lorusso V, et al: Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected
stage IB-IIIA non-small-cell lung cancer [Adjuvant Navelbine
International Trialist Association (ANITA)]: A randomised
controlled trial. Lancet Oncol. 7:719–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al: LACE Collaborative group, lung adjuvant
cisplatin evaluation: A pooled analysis by the LACE collaborative
group. J Clin Oncol. 26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Waller D, Peake MD, Stephens RJ, Gower NH,
Milroy R, Parmar MK, Rudd RM and Spiro SG: Chemotherapy for
patients with non-small cell lung cancer: The surgical setting of
the big lung trial. Eur J Cardiothorac Surg. 26:173–182. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudo Y, Shimada Y, Saji H, Kato Y, Yoshida
K, Matsubayashi J, Nagase S, Kakihana M, Kajiwara N, Ohira T, et
al: Prognostic factors for survival after recurrence in patients
with completely resected lung adenocarcinoma: Important roles of
epidermal growth factor receptor mutation status and the current
staging system. Clin Lung Cancer. 16:e213–221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Isaka T, Yokose T, Ito H, Nagata M,
Furumoto H, Nishii T, Katayama K, Yamada K, Nakayama H and Masuda
M: Correlations between the EGFR mutation status and
clinicopathological features of clinical Stage I lung
adenocarcinoma. Medicine (Baltimore). 94:e17842015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union against Cancer, TNM Classification of
Malignant Tumours7th. Wiley-Blackwell; Chichester, UK, Hoboken, NJ:
2010
|
|
14
|
Yatabe Y, Hida T, Horio Y, Kosaka T,
Takahashi T and Mitsudomi T: A rapid, sensitive assay to detect
EGFR mutation in small biopsy specimens from lung cancer. J Mol
Diagn. 8:335–341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshida K, Yatabe Y, Park JY, Shimizu J,
Horio Y, Matsuo K, Kosaka T, Mitsudomi T and Hida T: Prospective
validation for prediction of gefitinib sensitivity by epidermal
growth factor receptor gene mutation in patients with non-small
cell lung cancer. J Thoracic Oncol. 2:22–28. 2007. View Article : Google Scholar
|
|
16
|
Janjigian YY, Park BJ, Zakowski MF,
Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J and Azzoli
CG: Impact on disease-free survival of adjuvant erlotinib or
gefitinib in patients with resected lung adenocarcinomas that
harbor EGFR mutations. J Thorac Oncol. 6:569–575. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pennell NA, Neal JW, Chaft JE, Azzoli CG,
Janne PA, Govindan R, Evans TL, Costa DB, Rosovsky RP, Wakelee HA,
et al: SELECT: A multicenter phase II trial of adjuvant erlotinib
in resected early stage EGFR mutation-positive NSCLC. J Clin Oncol.
32:7514. 2014. View Article : Google Scholar
|
|
18
|
Kelly K, Altorki NK, Eberhardt WE, O'Brien
ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, et al:
Adjuvant erlotinib versus placebo in patients with stage IB-IIIA
non-small-cell lung cancer (RADIANT): A randomized, double-blind,
Phase III trial. J Clin Oncol. 33:4007–4014. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okabe T, Okamoto I, Tamura K, Terashima M,
Yoshida T, Satoh T, Takada M, Fukuoka M and Nakagawa K:
Differential constitutive activation of the epidermal growth factor
receptor in non-small cell lung cancer cells bearing EGFR gene
mutation and amplification. Cancer Res. 67:2046–2053. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamashita F, Azuma K, Yoshida T, Yamada K,
Kawahara A, Hattori S, Takeoka H, Zaizen Y, Kawayama T, Kage M and
Hoshino T: Prognostic value of EGFR mutation and ERCC1 in patients
with non-small cell lung cancer undergoing platinum-based
chemotherapy. PLoS One. 8:e713562013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park K, Tan EH, O'Byrne K, Zhang L, Boyer
M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, et al: Afatinib versus
gefitinib as first-line treatment of patients with EGFR
mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase
2B, open-label, randomised controlled trial. Lancet Oncol.
17:577–589. 2016. View Article : Google Scholar : PubMed/NCBI
|
